Investigated for treating COVID-19.
- TRADE NAME: Krintafel (GSK)
- INDICATIONS: indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection.
- CLASS: Antimalarial
- HALF-LIFE: ~15 days
- FDA APPROVAL DATE: 07/20/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: May cause hemolytic anemia in a fetus who is G6PD deficient. Treatment during pregnancy is not recommended
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/07/2024
